Tag: AstraZeneca
AstraZeneca to acquire Gracell Biotechnologies for $1.2bn to expand cell therapy capabilities
AstraZeneca has announced a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL) for an upfront cash payment of $1.0 billion, representing a 62% ... Read More
AstraZeneca, Ionis Pharmaceuticals get FDA approval of Wainua for ATTRv-PN
In a major development for hereditary transthyretin-mediated amyloidosis (ATTRv-PN or hATTR-PN) patients, the US Food and Drug Administration (FDA) has approved Wainua (eplontersen), developed by ... Read More
AstraZeneca to acquire Icosavax in $1.1bn deal to boost vaccine development
In a definitive move, AstraZeneca has entered into an agreement to acquire Icosavax, Inc., a U.S.-based biopharmaceutical company specializing in innovative vaccines. This acquisition, valued ... Read More
AstraZeneca’s Danicopan yields promising results in ALPHA Phase 3 trial in PNH
In a significant development in the healthcare industry, AstraZeneca has released positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA ... Read More
Absci collaborates with AstraZeneca for AI-designed oncology antibody
Absci Corporation (Nasdaq: ABSI), a leader in generative AI antibody discovery, announced a groundbreaking collaboration with AstraZeneca, a global biopharmaceutical company. This partnership aims to ... Read More
AstraZeneca launches Evinova to optimize clinical trials and patient care
AstraZeneca has announced the launch of Evinova, poised to become a leading provider in the digital health solutions domain. Backed by AstraZeneca and collaborating with ... Read More
FDA approves AstraZeneca’s Truqap for advanced breast cancer treatment
In a notable development in the field of oncology, the US Food and Drug Administration (FDA) has approved AstraZeneca’s Truqap (capivasertib) in combination with Faslodex ... Read More
AstraZeneca’s PACIFIC-2 Phase 3 trial for Imfinzi in NSCLC falls short of primary endpoint
In the latest development in oncology research, AstraZeneca's PACIFIC-2 Phase III trial, involving Imfinzi (durvalumab) concurrently administered with platinum-based chemoradiotherapy (CRT), did not achieve statistical ... Read More
AstraZeneca reports steady growth in 9M and Q3 2023 with core EPS increase
AstraZeneca has announced its financial results for the nine months (9M) and third quarter (Q3) of 2023, displaying solid financial performance with a focus on ... Read More
Innovative CKD management: AstraZeneca’s Zibotentan/Dapagliflozin advances to Phase III
Recent findings from the ZENITH-CKD Phase IIb trial, conducted by AstraZeneca, have demonstrated a significant decrease in albuminuria among CKD patients treated with a combination ... Read More